Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

14.46
-0.6900-4.55%
Pre-market: 14.20-0.2600-1.80%06:34 EDT
Volume:3.07M
Turnover:44.71M
Market Cap:2.46B
PE:-5.53
High:15.12
Open:14.63
Low:14.01
Close:15.15
Loading ...

UBS Downgrades Immunovant to Neutral, Price Target is $17

MT Newswires Live
·
12 mins ago

Immunovant downgraded to Neutral from Buy at UBS

TIPRANKS
·
1 hour ago

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Caution Deepens Amid Intensifying Tariff Escalations

MT Newswires Live
·
Yesterday

Immunovant Names New CEO, CFO

MT Newswires Live
·
Yesterday

BRIEF-Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications

Reuters
·
Yesterday

Immunovant CEO Salzmann Retires; Roivant Exec Venker Takes the Helm

Dow Jones
·
Yesterday

Immunovant Inc - Tiago Girao Appointed as CFO of Immunovant

THOMSON REUTERS
·
Yesterday

Immunovant Inc - Ind Cleared for Imvt-1402 in Sjd, Study to Initiate Summer 2025

THOMSON REUTERS
·
Yesterday

Immunovant Inc - Current Cash Balance Provides Runway Through Graves’ Disease Readout in 2027

THOMSON REUTERS
·
Yesterday

Immunovant Announces Next Phase of Growth With Roivant Including Changes to Its Leadership Team and Additional Indications SjÖGren’s Disease (Sjd) and Cutaneous Lupus Erythematosus (Cle) for Imvt-1402

THOMSON REUTERS
·
Yesterday

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

GlobeNewswire
·
Yesterday

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?

Insider Monkey
·
08 Apr

Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?

Insider Monkey
·
26 Mar

BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate

Reuters
·
21 Mar

Buy Rating Affirmed for IMVT-1402: Promising Study Results and Strategic Focus in FcRn Space

TIPRANKS
·
21 Mar

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Zacks
·
20 Mar

Immunovant Is Maintained at Buy by B of A Securities

Dow Jones
·
20 Mar

Immunovant price target lowered to $33 from $38 at BofA

TIPRANKS
·
20 Mar

Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Benzinga
·
20 Mar